EL7.AI
StocksMedium•16 November 2026•
3 min read

Larimar Completes Rolling Application for Accelerated Approval of Friedreich’s Ataxia Drug; Cash Runway at $128.7 Million

Key Facts

1Larimar had about $128.7 million in cash, cash equivalents and marketable securities on September 30, 2026, according to a preliminary, unaudited estimate.
2The company expects its cash to fund operations through late in the second quarter of 2027.
3Larimar completed its rolling biologics license application submission, seeking accelerated approval for nomlabofusp to treat Friedreich’s ataxia.
4The FDA could accept the application in early 2027, according to the company’s estimate.

Larimar Therapeutics said on November 9 that it had completed its rolling submission of a biologics license application to the U.S. Food and Drug Administration, seeking accelerated approval for nomlabofusp to treat Friedreich’s ataxia. The company said the application is based on increased frataxin in the skin as a potential surrogate endpoint and data from the ongoing open-label extension study. Completion of the submission puts the filing on the regulatory review track, with the timing of the application’s acceptance remaining subject to the company’s estimate. Larimar estimated that acceptance could occur in early 2027. Alongside this process, the company said it had $128.7 million in cash, cash equivalents and marketable securities as of September 30, 2026, according to a preliminary, unaudited estimate disclosed on November 9.

The $128.7 million balance is the company’s preliminary estimate at the end of September and includes cash, cash equivalents and marketable securities. The company did not describe the figure as audited in its disclosure, so it remains characterized as the announced estimate. In its November presentation, Larimar said the balance was expected to fund operations through late in the second quarter of 2027. The cash runway estimate therefore extends beyond the company’s expected early-2027 acceptance of its application. This provides a stated timeframe for the regulatory and operational tracks, without indicating that the drug has been approved.

The clinical program includes the pivotal Phase 3 FORWARD-FA study, which the company said is enrolling participants. The study was designed as a double-blind, placebo-controlled trial, with plans to enroll 100 to 150 participants. The protocol includes 18 months of treatment and participants who are able to walk and are between 2 and 40 years old. The company’s presentation also indicated that about two-thirds of planned participants are under 21 years old. Larimar described the study as a parallel confirmatory pathway for the accelerated approval application based on data from the open-label extension study.

The company included a safety update from the open-label extension study among the expected milestones for the first quarter of 2027. The update is part of the data Larimar said its license application relies on, as it seeks to use increased frataxin levels in the skin as a potential surrogate endpoint. The chief executive said the company’s team is preparing for a possible FDA review of the application, continuing the pivotal Phase 3 FORWARD-FA study and preparing for a potential U.S. launch after approval. She added: "As we support a potential FDA review and advance FORWARD-FA, our pivotal Phase 3 study, our team is preparing for a potential U.S. launch." The launch remains, in the company’s wording, contingent on approval.

LRMR shares closed at $3.02 on November 13, 2026, according to EL7 data. The close followed the company’s November 9 announcement that it had completed the application submission and disclosed its estimated cash balance at the end of September. No verified figures are available among the established facts for the stock’s trading range during the November 13 session or its comparison with a previous close. The next milestones identified by the company are expected application acceptance in early 2027 and a safety update in the first quarter of that year. Larimar expects its cash to fund operations through late in the second quarter of 2027.

Open on chart